Literature DB >> 20799357

Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy.

Michelle A Neben-Wittich, Paul D Brown, Ayalew Tefferi.   

Abstract

Myelofibrosis (MF) is characterized by cytopenias/cytoses, leukoerythroblastic blood picture, bone marrow fibrosis, and extramedullary hematopoiesis. Extremity bone pain can be a feature of MF. There has been one case report of a patient with MF and bone pain treated with radiation. We treated five patients with MF and extremity pain with radiation at our institution between 2004 and 2010. All patients had severe pain unresponsive to narcotic medication. Radiation was one fraction of 100 to 600 cGy. Most patients saw improvement in the pain within days and achieved a complete response within days to weeks.The response lasted between 1 month and 2 years. Retreatment was performed in four patients and achieved a durable response in three patients. No patients reported any acute or late side effects from radiation.Bone involvement in MF can cause disabling pain, but single-fraction low-dose radiation is a safe and effective treatment, often leading to a durable response. Retreatment is also safe and effective inpatients who experience recurrent pain.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20799357     DOI: 10.1002/ajh.21819

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  2 in total

1.  Extramedullary hematopoiesis at the posterior mediastinum in patient with hereditary spherocytosis: a case report.

Authors:  Sang Yoon Yeom; Jae Hong Lim; Kook Nam Han; Chang Hyun Kang; In Kyu Park; Young Tae Kim
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2013-04-09

2.  Intrathoracic extramedullary hematopoiesis presenting as tumor-simulating lesions of the mediastinum in α-thalassemia: A case report.

Authors:  Jun An; Yimin Weng; Jinyuan He; Yun Li; Shaohong Huang; Songwang Cai; Junhang Zhang
Journal:  Oncol Lett       Date:  2015-08-12       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.